2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.
Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, jco2402219. PMID: 40048689, DOI: 10.1200/jco-24-02219.Peer-Reviewed Original ResearchMelanoma brain metastasesOverall survivalBrain metastasesAnti-vascular endothelial growth factor therapyMedian intracranial progression-free survivalFour-year OS ratesIntracranial progression-free survivalResponse rateCirculating angiopoietin-2Median overall survivalTrial of pembrolizumabYears of pembrolizumabDose of bevacizumabProgression-free survivalPhase II trialGrowth factor therapyAdverse event ratesAssociated with responseOS ratesPD-1Radiation necrosisLocal therapyOn-therapyMetastatic tumorsFactor therapy
2023
Comparing Patient-Reported Outcomes Among Anti-TNF-Experienced Patients with Crohn’s Disease Initiating Vedolizumab Versus Ustekinumab
Kappelman M, Lewis J, Zhang X, Lin F, Weisbein L, Chen W, Burris J, Dorand J, Parlett L, Haynes K, Nair V, Kaul A, Dobes A, Long M. Comparing Patient-Reported Outcomes Among Anti-TNF-Experienced Patients with Crohn’s Disease Initiating Vedolizumab Versus Ustekinumab. Digestive Diseases And Sciences 2023, 68: 3413-3420. PMID: 37115362, DOI: 10.1007/s10620-023-07942-0.Peer-Reviewed Original ResearchConceptsShort Crohn's Disease Activity IndexDisease activity indexCrohn's diseasePain interferenceCorticosteroid useTreatment persistenceSecondary outcomesAnti-tumor necrosis factor therapyOutcomes Measurement Information System (PROMIS) domainsCrohn's Disease Activity IndexEffectiveness of vedolizumabHigher corticosteroid useLower treatment persistenceNecrosis factor therapyCo-primary outcomesPatient-reported outcomesInternet-based cohort studyLogistic regression modelsIBD PartnersCohort studyExperienced patientsFactor therapyPrimary outcomeBiological therapySteroid use
2022
Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease
Kappelman M, Adimadhyam S, Hou L, Wolfe A, Smith S, Simon A, Moyneur É, Reynolds J, Toh S, Dobes A, Parlett L, Haynes K, Selvan M, Ma Q, Nair V, Burris J, Dorand J, Dawwas G, Lewis J, Long M. Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease. The American Journal Of Gastroenterology 2022, 118: 674-684. PMID: 36508681, DOI: 10.14309/ajg.0000000000002068.Peer-Reviewed Original ResearchConceptsCrohn's diseaseCause hospitalizationCD hospitalizationsTreatment persistenceSecondary outcomesAntitumor necrosis factor therapyReal-world comparative effectiveness studiesAntitumor necrosis factorLarge US insurerNecrosis factor therapyTreatment persistence ratesAnti-TNF treatmentBaseline clinical characteristicsRetrospective cohort studyComparative effectiveness studiesRoute of administrationDiverse US populationLongitudinal claims dataRefractory populationClinical characteristicsCohort studyFactor therapyPrimary outcomePatient preferencesNecrosis factorRecommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel
Dulai P, Rai V, Raffals L, Lukin D, Hudesman D, Kochhar G, Damas O, Sauk J, Levy A, Sofia M, Tuskey A, Deepak P, Yarur A, Afzali A, Ananthakrishnan A, Cross R, Hanauer S, Siegel C. Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel. The American Journal Of Gastroenterology 2022, 117: 1288-1295. PMID: 35416799, PMCID: PMC9437635, DOI: 10.14309/ajg.0000000000001775.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsModerate-severe flaresUlcerative colitisAntitumor necrosis factor therapyModerate-severe ulcerative colitisNecrosis factor therapyRAND appropriateness panelMethylprednisolone 40Naive patientsPostdischarge managementSteroid dosingStool frequencyRectal bleedingTherapy initiationAdverse eventsFactor therapyInpatient managementPostdischarge careHospital admissionLower endoscopyDischarge planningLower riskPatientsDischarge criteriaAppropriate managementHigh doses
2020
Screening for Latent Tuberculosis in Children With Immune-mediated Inflammatory Diseases Treated With Anti-tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests
Gİrİt S, Ayzit Atabek A, Şenol E, KoÇkar Kizilirmak T, Pekcan S, GÖktaŞ Ş, Öktem S, KasapÇopur Ö, ÇokuĞraŞ H. Screening for Latent Tuberculosis in Children With Immune-mediated Inflammatory Diseases Treated With Anti-tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests. Archives Of Rheumatology 2020, 35: 020-028. PMID: 32637916, PMCID: PMC7322294, DOI: 10.5606/archrheumatol.2020.7294.Peer-Reviewed Original ResearchTuberculin skin testLatent tuberculosis infectionValues of TSTSixth monthT-SPOTSkin testInflammatory diseasesTuberculosis testAnti-tumor necrosis factor therapyAnti-tumor necrosis factor treatmentNecrosis factor therapyAnti-TNF agentsAnti-TNF therapyProspective multicentric studyNecrosis factor treatmentFactor therapyLatent tuberculosisTuberculin skinTuberculosis infectionMulticentric studyLocal guidelinesTB testFactor treatmentPatientsMonths
2019
Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry
Van Voorhees A, Mason M, Harrold L, Guo N, Guana A, Tian H, Herrera V, Strober B. Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry. Journal Of Dermatological Treatment 2019, 32: 302-309. PMID: 31581919, DOI: 10.1080/09546634.2019.1656797.Peer-Reviewed Original ResearchConceptsAnti-tumor necrosis factor therapyCorrona Psoriasis RegistryNecrosis factor therapySevere psoriasisPsoriasis RegistryBiologic therapyFactor therapyAnti-TNF initiatorsEnrollment of patientsUnmet treatment needLogistic regression modelingReal-world studyPatient demographicsInsufficient respondersShort followDisease characteristicsFemale sexTreatment needsInsufficient responsePatientsUnmet needPsoriasisDecreased likelihoodTherapySmall sample size
2018
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2
Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD, Huang Y, Rahbari NN, Roberge S, Wang D, Gomes-Santos IL, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Tolaney SM, Krop IE, Duda DG, Boucher Y, Fukumura D, Jain RK. Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Science Translational Medicine 2018, 10 PMID: 29540614, PMCID: PMC5936748, DOI: 10.1126/scitranslmed.aag0945.Peer-Reviewed Original ResearchConceptsVEGF therapyInterleukin-6Breast cancerMouse modelAnti-vascular endothelial growth factor therapyEndothelial growth factor therapyTumor vasculatureAnti-VEGF therapyAnti-VEGF treatmentIL-6 blockadeGrowth factor therapyIL-6 productionFGF-2Up-regulates IL-6Second mouse modelFGF-2 expressionTumor cell proliferationFactor therapyGrowth factor 2Proinflammatory factorsMetastatic sitesBC patientsObese miceReceptor inhibitionSystemic concentrationsIncidence of endophthalmitis after intravitreal injections at a tertiary care hospital
Zafar S, Hamid A, Bin Mahmood SU, Burq MA, Maqsood N. Incidence of endophthalmitis after intravitreal injections at a tertiary care hospital. Canadian Journal Of Ophthalmology 2018, 53: 94-97. PMID: 29631833, DOI: 10.1016/j.jcjo.2017.07.027.Peer-Reviewed Original ResearchConceptsIncidence of endophthalmitisIntravitreal injectionAnti-vascular endothelial growth factor therapyEndothelial growth factor therapySingle-center retrospective studyAga Khan University HospitalTertiary care hospitalGrowth factor therapyCases of endophthalmitisRole of antibioticsOperating room settingPostinjection antibioticsFactor therapyCare hospitalRetrospective studyUniversity HospitalInjection riskSurgical settingEndophthalmitisUnnecessary useRoom settingStudy periodInjectionHospitalIncidence
2017
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas
Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. Journal Of Neuro-Oncology 2017, 132: 181-188. PMID: 28116649, PMCID: PMC5588922, DOI: 10.1007/s11060-016-2357-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, AlkylatingBrain NeoplasmsChemotherapy, AdjuvantCombined Modality TherapyDacarbazineDrug Therapy, CombinationFemaleGliomaHumansMaleMiddle AgedNeuropsychological TestsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsTemozolomideTreatment OutcomeVascular Endothelial Growth Factor AConceptsHigh-grade gliomasPhase I trialI trialArm 2Arm 1Anti-vascular endothelial growth factor therapyAdult Brain Tumor ConsortiumEndothelial growth factor therapyRecombinant human fusion proteinGrowth factorFull treatment courseGrowth factor therapyPlacental growth factorSoluble decoy receptorHuman fusion proteinKPS 90Primary endpointFactor therapyDay regimenMedian ageTreatment courseArm 3Disease progressionMedian numberRadiation therapy
2016
Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature
Ashraf M, Souka A, Adelman R. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. British Journal Of Ophthalmology 2016, 100: 1596. PMID: 27231313, DOI: 10.1136/bjophthalmol-2016-308388.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaOptical coherence tomographyMacular edemaAnti-vascular endothelial growth factor therapyIntravitreal anti-vascular endothelial growth factorAnti-vascular endothelial growth factorEndothelial growth factor therapyFluorescein angiography findingsAnti-VEGF therapyAnti-VEGF agentsGrowth factor therapyCourse of treatmentCommon prognostic indicatorsEndothelial growth factorFactor therapyMost patientsVisual outcomeAngiography findingsChoroidal thicknessLarge RCTsTreatment regimenOCT parametersVisual acuityPrognostic indicatorDifferent RCTs
2015
Recent developments in laser treatment of diabetic retinopathy
Yun SH, Adelman RA. Recent developments in laser treatment of diabetic retinopathy. Middle East African Journal Of Ophthalmology 2015, 22: 157-163. PMID: 25949072, PMCID: PMC4411611, DOI: 10.4103/0974-9233.150633.Peer-Reviewed Original ResearchConceptsDiabetic retinopathyAntivascular endothelial growth factor therapyEndothelial growth factor therapyProliferative diabetic retinopathyGrowth factor therapyPattern scan laserDiabetic retinopathy treatmentLaser treatmentFactor therapyMacular edemaLaser photocoagulationRetinopathy treatmentLaser therapyRetinopathyScan laserTherapyTreatmentEdemaPhotocoagulationMainstay
2005
Delayed Arteriogenesis in Hypercholesterolemic Mice
Tirziu D, Moodie KL, Zhuang ZW, Singer K, Helisch A, Dunn JF, Li W, Singh J, Simons M. Delayed Arteriogenesis in Hypercholesterolemic Mice. Circulation 2005, 112: 2501-2509. PMID: 16230502, DOI: 10.1161/circulationaha.105.542829.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApolipoprotein B-48Apolipoproteins BBlood Flow VelocityDisease Models, AnimalEndothelium, VascularFemoral ArteryHumansIn Vitro TechniquesIschemiaMagnetic Resonance ImagingMiceMice, KnockoutNeovascularization, PhysiologicOligonucleotide Array Sequence AnalysisReceptors, LDLUmbilical VeinsConceptsFemoral artery ligationControl miceLaser Doppler imagingArtery ligationTissue perfusionDay 7Doppler imagingReceptor 1Strain-matched control miceVascular cell adhesion molecule-1Monocyte/macrophage influxCell adhesion molecule-1Hypercholesterolemic low-density lipoproteinDistal limb perfusionMacrophage scavenger receptor 1Growth factor therapyIschemia-induced angiogenesisRestoration of perfusionAdhesion molecule-1Arterial blood flowHypoxia-inducible factor-1alphaLow-density lipoproteinScavenger receptor 1Controls 3 daysFactor therapy
2000
Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus
Simons M, Bonow R, Chronos N, Cohen D, Giordano F, Hammond H, Laham R, Li W, Pike M, Sellke F, Stegmann T, Udelson J, Rosengart T. Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus. Circulation 2000, 102: e73-86. PMID: 10982554, DOI: 10.1161/01.cir.102.11.e73.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis Inducing AgentsAnimalsClinical Trials as TopicCoronary AngiographyCoronary VesselsEndothelial Growth FactorsFibroblast Growth Factor 2Genetic TherapyHeart DiseasesHumansLymphokinesMagnetic Resonance ImagingNeovascularization, PhysiologicPatient SelectionTomography, Emission-ComputedTomography, Emission-Computed, Single-PhotonVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsClinical trialsCoronary angiogenesisAdvanced ischemic heart diseaseAngiogenic growth factor therapySide effect profileIschemic heart diseaseGrowth factor therapyAppropriate patient populationAmerican Heart AssociationNew treatment strategiesTherapeutic end pointRoute of administrationBiology of angiogenesisNew blood supplyFactor therapyCoronary diseaseEffect profilePatient populationHeart AssociationHeart diseaseTreatment strategiesBlood supplyTherapeutic strategiesPreclinical investigationsTherapeutic angiogenesis
1999
Clinical Guidelines and Pharmacist Intervention Program for HIV‐Infected Patients Requiring Granulocyte Colony‐Stimulating Factor Therapy
Engles‐Horton L, Skowronski C, Mostashari F, Altice F. Clinical Guidelines and Pharmacist Intervention Program for HIV‐Infected Patients Requiring Granulocyte Colony‐Stimulating Factor Therapy. Pharmacotherapy The Journal Of Human Pharmacology And Drug Therapy 1999, 19: 356-362. PMID: 10221375, DOI: 10.1592/phco.19.4.356.30938.Peer-Reviewed Original ResearchConceptsIntervention periodPreintervention periodFactor therapyG-CSFGranulocyte colony-stimulating factor therapyHuman immunodeficiency virus (HIV) infectionColony-stimulating factor therapyPharmacist intervention programPharmacist-based interventionMean hospital stayImmunodeficiency virus infectionHospital medical information systemG-CSF dosesNumber of patientsMedical house staffTherapeutics subcommitteeHospital stayPharmacist interventionsChart reviewHospitalized patientsClinical pharmacistsImmunodeficiency syndromePatient morbidityPharmacy costsClinical guidelines
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply